MNC pharma: Seek opportunity! - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MNC pharma: Seek opportunity!

Nov 24, 2004

According to newspaper reports, a leading consultancy firm has estimated that the Indian pharmaceutical sector will become a US$ 25 bn industry by the year 2012, up from its current levels of about US$ 6.5 bn. According to the report, while the market in India will expand, further growth will be driven by exports of pharmaceutical products. While Indian companies are likely to grab this opportunity with both the hands, in this article we have tried to understand how MNC pharma companies are poised to benefit from this opportunity by analyzing their recent performance. There are many MNC pharma companies operating in India. While some of them have really entrenched themselves in the country, others operate merely as a trading entity. Companies such as Aventis, Glaxo and Pfizer have full fledged operations in India, others like Abbott, Sanofi, Novartis are more or less trading companies.

In the chart above, we can see that these companies have shown impressive performance in terms of growth, which is more in line with the market growth rate. While the consolidated growth of these five companies in the first nine-months of 2004 is about 11%, some have outperformed the others. While MNC companies largely have shied away from introducing new products, Novartis and Aventis have taken lead in last two years by launching new products in the Indian markets even before the new patent regime is in place.

However, the new patent regime that will come into force from 2005 will be significant for these MNC pharma companies, which are preparing themselves for the same. Most of the foreign companies have restructured themselves, be it Glaxo, Pfizer or Novartis to take advantage of the new patent regime. Although, the new patent regime will come in force from 2005, we do not see any significant impact in the topline of these companies in first two years (2005 and 2006). But in the long run, these MNC companies will certainly gain market share in high value patented products.

Apart from this, the other opportunity that exists for MNC companies in India is outsourcing. Most companies in western regulated markets are facing severe price competition from the low cost generics manufactured in India. These global corporations are likely to look at cutting costs by out-sourcing their manufacturing to low cost countries such as India and presumably, the best choice for them would be their own subsidiaries. The example of this phenomenon is Aventis, which is already making bulk drugs for its parent company. In fact, 22% of Aventis revenues are from outsourcing activity. Similarly, in case of Glaxo, it is supplying drugs manufactured in India to its parent company.

Be it selling new drugs in Indian markets or supplying drugs to their parent companies in western world, Indian arms of the global pharma giants are in for a change in their growth pattern in next few years. While the markets have realised this, there are still opportunities available for long-term investors to invest in the sector's growth trajectory.


Equitymaster requests your view! Post a comment on "MNC pharma: Seek opportunity!". Click here!

2 Responses to "MNC pharma: Seek opportunity!"

d. jacob soundararaj

Feb 19, 2011

Competent & seasoned professional with over 25 years of well- honed experience in business development, marketing, channel management, team management & brand promotion in the Pharmaceutical Industry with excellent understanding of business dynamics and updated market knowledge combined with creative strategies.

Seeking a position south india based (Bangalore) covering south india

Like 

dheeman das

May 7, 2009

I am Fresher need a job in any Pharma MNC companies in any field either in market production.

Like 
  
Equitymaster requests your view! Post a comment on "MNC pharma: Seek opportunity!". Click here!

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 25, 2020 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS